OncoMatch/Clinical Trials/NCT07260175
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
Is NCT07260175 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ivosidenib for cholangiocarcinoma.
Treatment: Ivosidenib — This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: IDH1 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: adjuvant systemic chemotherapy — adjuvant
Patient finished adjuvant systemic SOC chemotherapy (with regimens allowed per the protocol) directly prior to trial inclusion.
Cannot have received: IDH1 inhibitor
Patient received previous therapy with an IDH1 inhibitor.
Lab requirements
Blood counts
adequate to allow targeted therapy with ivosidenib at investigator's discretion and IB
Kidney function
adequate to allow targeted therapy with ivosidenib at investigator's discretion and IB
Liver function
adequate to allow targeted therapy with ivosidenib at investigator's discretion and IB
Hematological, hepatic and renal function parameters adequate to allow targeted therapy with ivosidenib at investigator´s discretion and IB.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify